The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03037463
Recruitment Status :
Active, not recruiting
First Posted : January 31, 2017
Last Update Posted : May 8, 2019
University of Southern California
Information provided by (Responsible Party):
Sarah Hamm-Alvarez, University of Southern California
The purpose of this study is to assess whether tear secretion in patients with Parkinson's disease will be altered to exhibit a characteristic or diagnostic biomarker profile, that will be reflected in changes in the protein composition of tear fluid, which can be measured relatively easily, cost-effectively, and non-invasively. Tear fluid samples will be collected from Parkinson's patients, and through biochemical assays, the profile of proteins in tears will be characterized and compared to that from control subjects. The profiles will be analyzed with respect to any differences between Parkinson's patients and control subjects. If differences appear, the levels of these potential biomarkers in Parkinson's patients will be compared to the severity of their disease.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
35 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The investigators will recruit participants with Parkinson's disease and controls from the Parkinson's Disease and Movement Disorder Center at the University of Southern California (USC) and from the surrounding community.
established Parkinson's Disease for at least 6 months
Healthy controls without neurological illness
currently taking anti-cholinergic medication
have an exposure to neuroleptic medications other than Quetiapine or Clozapine in the 6 months prior to screening
have an active eye infection or have had eye surgery within 3 months prior to screening
control subjects will be excluded if they have a history of neurological disease
PD subjects will be excluded if they have an atypical Parkinsonian syndrome